菠萝蛋白酶酶性清创(Nexobrid®)去除烧伤焦痂:欧洲共识
欧洲共识会议基于专家在500余例成人和儿童患者中应用酶性清创的经验,针对适应证、疼痛管理与麻醉、应用时机、应用技术、干预后护理、酶性清创后皮肤移植、失血、培训策略与学习曲线及未来研究需求等领域,提供68条共识声明;88.2%的声明达成一致共识,仅3条声明共识度最低为70%。该共识文件可作为酶性清创使用的初步指南,提供面向使用者的推荐,直至有进一步证据和系统指南可用。
要点
- 深度部分厚度和全层烧伤应尽早清创和/或去除焦痂,72小时内去除焦痂可减少细菌定植、感染和住院时间。
- 酶性清创是去除烧伤焦痂的有力工具,可减少失血、自体皮肤移植需求和需手术切除的创面数量。
- 共识提供68条酶性清创使用声明,88.2%声明达成一致共识,仅3条声明共识度最低为70%。
核心结论
- 酶性清创是去除烧伤焦痂的有力工具,可减少失血、自体皮肤移植需求和需手术切除的创面数量。
- 该共识文件可作为酶性清创使用的初步指南,提供面向使用者的推荐,直至有进一步证据和系统指南可用。
研究设计与样本
- 欧洲共识会议基于共识专家组成员在500余例成人和儿童患者中应用酶性清创的相互经验,提供应用声明。
主要发现
- 共识共提供68条酶性清创使用声明,88.2%的声明达成一致共识,仅3条声明共识度最低为70%。
关键数值与推荐
- 深度部分厚度和全层烧伤应尽早清创和/或去除焦痂,以控制创面微生物负荷并通过保守治疗或皮肤移植实现早期创面闭合。
- 保留有活力真皮并早期创面闭合被视为减少瘢痕相关并发症(如功能受限和/或不美观瘢痕形成)的必要步骤。
- 72小时内早期去除焦痂可减少细菌创面定植、感染和住院时间,从而改善烧伤创面治疗结局。
临床怎么用
- 共识声明涉及适应证、疼痛管理与麻醉、应用时机、应用技术、干预后护理、酶性清创后皮肤移植、失血、培训策略与学习曲线及未来研究需求。
- 该共识文件可作为酶性清创使用的初步指南,提供面向使用者的推荐,直至有进一步证据和系统指南可用。
局限性
- 该共识文件为初步指南,需等待进一步证据和系统指南可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early debridement and/or eschar removal is regarded as a significant step in the treatment of deep partial and full thickness burns. It aims to control wound bioburden and allows early wound closure by conservative treatment or skin grafting. Preservation of viable dermis accompanied by early wound closure, is regarded as a necessary step to reduce scar related complication, e.g. functional limitations and/or unaesthetic scar formation. Aside from the classical techniques of surgical excision as tangential excision for eschar removal, hydro-surgery, maggot therapy, laser, enzymatic debridement have been described as additional techniques in the burn surgeon's armamentarium. It is widely accepted that early eschar removal within 72h improves the outcome of burn wound treatment by reducing bacterial wound colonization, infection and length of hospital stay. In contrast, the right technique for eschar removal is still a matter of debate. There is increasing evidence that enzymatic debridement is a powerful tool to remove eschar in burn wounds, reducing blood loss, the need for autologous skin grafting and the number of wounds requiring surgical excision. In order to assess the role and clinical advantages of enzymatic debridement by a mixture of proteolytic enzymes enriched in Bromelain (Nexobrid®) beyond the scope of the literature and in view of users' experience, a European Consensus Meeting was scheduled. The aim was to provide statements for application, based on the mutual experience of applying enzymatic debridement in more than 500 adult and pediatric patients by the consensus panelists. Issues to be addressed were: indications, pain management and anesthesia, timing of application, technique of application, after-intervention care, skin grafting after enzymatic debridement, blood loss, training strategies and learning curve and areas of future research needs. Sixty-eight (68) consensus statements were provided for the use of enzymatic debridement. The degree of consensus was remarkably high, with a unanimous consensus in 88.2% of statements, and lowest degree of consensus of 70% in only 3 statements. This consensus document may serve as preliminary guideline for the use of enzymatic debridement with user-oriented recommendations until further evidence and systematic guidelines are available.
引用
- Hirche C, Citterio A, Hoeksema H, et al. Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: An European consensus. Burns. 2017. PMID: 29033046. doi:10.1016/j.burns.2017.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。